myo stock — Myomo, Inc. (MYO) Stock Overview
Myomo, Inc. (MYO) — Stock Overview
myo stock refers to the publicly traded shares of Myomo, Inc., listed on the NYSE American under the ticker MYO. This article explains what myo stock represents, how the company is structured, where it trades, and the main stock-related facts and investor considerations. Readers will gain an accessible primer on Myomo’s business, products, key financial and market data, risks specific to myo stock, and where to find authoritative filings and quotes. For live trading of myo stock and custody options, consider Bitget and Bitget Wallet for secure access and order execution.
Company profile
Myomo, Inc. is a wearable medical robotics company focused on designing, manufacturing, and selling myoelectric orthoses. The company’s flagship product family, MyoPro, is an elbow-and-hand orthosis that uses myoelectric sensors to detect residual muscle signals and assist users with limb movement. Myomo targets clinical populations that include stroke survivors, people with spinal cord injury, brachial plexus injury, and various neuromuscular disorders.
Headquartered in the United States, Myomo was founded with the mission to restore mobility and independence for individuals with upper-limb paralysis or weakness. The company’s operations combine product engineering, clinical support, and device distribution through orthotics and prosthetics providers, clinics, and institutional customers.
Ticker and market listing
- Ticker symbol: MYO
- Primary exchange: NYSE American
- Trading currency: USD
- Market classification: micro-cap / small-cap company (depending on prevailing market capitalization)
- Typical US trading hours: regular session for NYSE American-listed securities (pre-market and after-hours liquidity may be limited)
Investors looking to trade myo stock should be aware that securities classified as micro-cap or small-cap often show greater intraday volatility and wider bid-ask spreads. For secure execution and custody, Bitget offers trading infrastructure and Bitget Wallet can be used for related digital asset workflows where applicable.
Historical background
Founding and corporate history
Myomo began as a technology-driven medical device company focused on translating myoelectric control systems into wearable orthoses. The company developed prototypes and clinical partnerships to validate its MyoPro family for users with upper-limb impairment. Over a series of product development and commercialization milestones, Myomo transitioned to a direct and channel-based sales model servicing clinics, orthotics/prosthetics providers, and institutional buyers.
Key corporate milestones have included product iterations (e.g., enhancements that improved form factor, control algorithms, and battery life), notable clinical case studies and published outcomes demonstrating patient benefits, and expansion of sales and distribution pathways to reach veterans’ health providers and international partners.
Public listing and IPO (if applicable)
Myomo became a publicly traded company via listing on a US exchange under the ticker MYO. Since listing, the company has occasionally raised additional capital through public or private offerings and announced financing arrangements to support operations, product development, and commercialization. As with many emerging medical-device companies, Myomo's access to capital and periodic financing activities are material to the company’s balance sheet and investor outlook.
As of the dates cited in the references below, investors should consult the company’s SEC filings and press releases for a detailed timeline of public offerings, any ticker history, and other corporate actions.
Business operations and products
Core products (MyoPro family)
The MyoPro product line is a family of myoelectric orthoses designed to assist people who retain some muscle activity but have compromised limb control. Key aspects of the MyoPro family include:
- Myoelectric control: Sensors on the device detect electrical activity from the wearer’s residual muscles. The system amplifies and translates these signals into motorized assistance, enabling functional movement where voluntary control is reduced.
- Clinical applications: MyoPro devices are intended for individuals recovering from stroke, living with spinal cord injury, suffering brachial plexus injury, or managing neuromuscular disorders such as multiple sclerosis or cerebral palsy.
- Product iterations: The company has released updates across hardware and software generations (for example, improved controllers, lighter frames, and updated firmware), marketed under family names such as MyoPro2 and MyoPro2+ in more recent product cycles to improve control fidelity and patient comfort.
- Features: Typical features include adjustable assistance levels, rechargeable batteries, configurable control modes (to match individual muscle patterns), and clinician-facing tools for fitting and tuning the device.
MyoPro is positioned as a clinically oriented assistive technology rather than a cosmetic prosthesis — its primary role is to restore function and improve activities of daily living for users with partial muscle signals.
Sales channels and markets
Myomo distributes its products through multiple channels:
- Orthotics and prosthetics providers and clinics: Professional fittings and clinical support are commonly required for device prescription and patient training.
- Institutional customers: The U.S. Department of Veterans Affairs and other institutional payers or providers have been sources of orders in certain cases.
- Distributors and international partners: Myomo has pursued partnerships for select international markets, including European distributors.
- Direct sales and clinical networks: The company maintains a mix of direct sales efforts and partnerships to reach users and prescribers.
Geographic footprint centers on the U.S. market, with selective expansion efforts into Europe and other regions depending on regulatory and reimbursement pathways.
Financial overview
Note: The following financial summaries are intended as a structured overview. For the most recent, audited figures and quarter-to-quarter amounts, consult the company’s SEC filings and official press releases.
Key financial metrics
- Revenue: Myomo historically reports modest revenue relative to larger medical-device peers, reflecting niche product focus and selective market penetration. Revenue trends have shown variable quarter-to-quarter growth as commercialization advances.
- Net income / losses: The company has reported net losses in several periods, consistent with many small medical-device companies investing in commercialization and product development.
- EPS: Reported diluted earnings per share have historically been negative in periods when net losses were recorded.
- Market capitalization: myo stock is typically classified in the micro-cap to small-cap range; market cap fluctuates with share price and is available on market-data services.
As of June 30, 2024, per major market-data pages and company disclosures, myo stock’s market capitalization and recent trading liquidity placed it in the micro-cap cohort (reporting dates for market metrics vary by source). Readers should reference live quotes for up-to-date numeric values.
(Source examples: official SEC filings, company press releases, Yahoo Finance, MarketWatch for numeric snapshots.)
Balance sheet & cash position
Myomo’s balance sheet typically shows limited cash reserves relative to larger peers, with ongoing operating expenditures for sales, clinical support, and R&D. The company has used a combination of equity offerings, debt, and financing arrangements to support operations when necessary. Specific cash-on-hand, short-term debt, and other liquidity indicators are disclosed in periodic 10-Q and 10-K filings.
As of the most recent quarterly filing available in the references below, the company disclosed its cash and cash equivalents, short-term liabilities, and any material financing arrangements or loan facilities. Investors evaluating myo stock should monitor quarterly filings for updates on liquidity and capital-raising needs.
Recent quarterly/annual performance
Recent quarterly and annual results for Myomo have highlighted:
- Revenue momentum or contractions tied to device sales and service adoption.
- Operating losses reflecting investments in commercialization and administrative costs.
- Periodic financing activities announced to maintain runway.
As of the reporting dates noted in the company's investor materials and SEC filings, management commentary has focused on driving clinical adoption, expanding referral networks, and improving device throughput and service delivery. For exact quarterly metrics and management guidance (if any), consult the cited earnings releases and 10-Q/10-K statements.
Stock price history and market data
Recent trading range and performance
myo stock has historically exhibited wide intraday ranges and volatility compared with larger-cap stocks. The 52-week high and low, daily typical ranges, and recent percent moves are available via market-data providers; investors should consult live quote pages on their trading platform of choice (such as Bitget’s market interface) for current figures.
As of June 30, 2024, major market-data sources provided the 52-week range, recent trading activity, and day-to-day percentage moves for MYO. These metrics change daily and are essential for assessing current risk and potential price slippage when trading myo stock.
Shares outstanding, float, and volume
- Shares outstanding: The total shares outstanding for Myomo are disclosed in the latest annual or quarterly filing and will change with equity raises or share-based compensation.
- Public float: A portion of total shares is typically held by insiders and institutions; the publicly tradeable float is commonly smaller than total shares outstanding for many micro-cap companies.
- Average trading volume and short interest: myo stock’s average volume has been relatively low compared with larger listed equities, and short interest data (where reported) can be found through market-data providers.
Low float and modest average volume can amplify price movements in myo stock on news or trading activity.
Market cap and classification
myo stock’s market capitalization places it in the micro-cap or small-cap classification depending on the share price at any given time. This classification has implications:
- Liquidity: Micro-cap stocks typically have lower liquidity and wider bid-ask spreads.
- Volatility: Price volatility tends to be higher than for mid- and large-cap stocks.
- Coverage: Analyst coverage and institutional investor interest are often limited for micro-cap names.
Investors and traders should factor these characteristics into trading plans and position sizing when considering myo stock.
Analyst coverage and price targets
Analyst coverage for myo stock is generally limited compared with larger medical-device names. Where coverage exists, published analyst notes or price targets should be reviewed with caution because micro-cap companies often exhibit higher model sensitivity and less frequent updates.
For example, selective published targets and analyst opinions have appeared in market commentary and financial websites. As of mid-2024, representative price targets that appeared in public summaries were reported on various platforms; however, readers should confirm dates and authorship in the original analyst publications or aggregated market-data pages.
Caveat: Price targets on micro-cap stocks can diverge widely and may not account for the latest company filings or clinical developments. Always cross-reference analyst commentary with primary company disclosures.
Ownership and insider activity
Ownership of myo stock typically includes a mix of management and board insider holdings, institutional investors (often small in number due to micro-cap status), and retail holders. Insider transactions (purchases or sales) are reported via SEC Form 4 filings and are material for investors tracking management alignment.
Institutional ownership trends and recent insider trades are available through company filings and public market-data pages. Significant insider selling or dilution through equity raises can materially affect the share base and market perception of myo stock.
Trading considerations and risk factors
This section outlines general trading and company-specific risks relevant to myo stock. The list is not exhaustive; investors should read SEC filings for a comprehensive set of risk disclosures.
Liquidity and volatility
- myo stock may have low daily trading volume compared with larger-cap securities, increasing the potential for price impact when placing trades.
- Wider bid-ask spreads and episodic spikes in volume can create sharp price moves.
- Limit orders and staged executions are common tools to mitigate slippage when trading lower-liquidity stocks.
Business and clinical adoption risks
- Reimbursement: Adoption often depends on insurance reimbursement and coverage policies; changes or delays in reimbursement can affect sales.
- Clinical adoption: Real-world clinical uptake requires clinician education, referrals, and demonstrated outcomes; adoption rates can be slower than management targets.
- Competition: Other rehabilitation technologies and alternative therapies may compete for the same patient populations.
- Regulatory: Medical-device regulations and any product-submission requirements pose ongoing compliance needs.
Financial risks
- Recurring losses and negative operating cash flow are common for early-stage medical-device companies and may necessitate future financing.
- Dilution: Future capital raises can dilute existing shareholders.
- Debt or financing obligations: Any loan facilities or financing arrangements can impose covenants or repayment obligations that affect financial flexibility.
Investors should read the company’s risk-factor sections in SEC filings and monitor liquidity events, capital raises, and financing terms that directly affect myo stock.
Recent news and developments
As of the reporting dates stated in company press releases and market-data summaries, Myomo has issued periodic updates on quarterly results, conference presentations, financing arrangements, and product milestones. Examples of the types of news items that materially affect myo stock include:
- Quarterly earnings releases showing revenue and operating results.
- Announcements of loan facilities or other financing intended to extend runway.
- Presentations at investor conferences or medical conferences highlighting clinical data.
- Product announcements or regulatory clearances that expand addressable markets or improve device features.
As of June 30, 2024, per company press releases and market-data providers, the latest quarter’s highlights and any material financing events were summarized in the company’s investor relations materials and SEC filings. Investors should review the official press releases and 8-K filings for event dates and full details.
Regulatory and legal matters
Myomo operates in a regulated medical-device environment. Regulatory matters of interest include:
- Device classification and any required clearances or approvals for market access in different jurisdictions.
- Compliance with manufacturing quality systems and adverse event reporting obligations.
- Material legal proceedings: any pending litigation or claims material to the company’s operations would be disclosed in SEC filings.
If there are material regulatory approvals or legal proceedings, the company’s 10-K, 10-Q, and 8-K filings will present the official statements and timelines. Investors in myo stock should monitor those filings for developments.
Investor relations
Investors can access official Myomo filings, earnings releases, investor presentations, and corporate disclosures through the company’s investor relations channel and the SEC’s EDGAR system. Typical resources include:
- Quarterly (10-Q) and annual (10-K) reports filed with the SEC.
- Current reports on Form 8-K for material events.
- Proxy statements and Form 4 filings for insider transactions.
- Investor presentations and press releases posted by the company.
For live market quotes and order execution, use a regulated trading platform — Bitget provides market data access, order execution, and custody options. For wallet-related activities tied to digital assets or Web3, Bitget Wallet is the recommended choice.
See also
- Wearable robotics
- Myoelectric orthoses and prosthetics
- Medical-device investing and micro-cap equities
- Rehabilitation technology companies and comparable public peers
- Basics of SEC filings and how to read 10-Q/10-K reports
References
- Company SEC filings and investor relations press releases (check the company’s 10-Q, 10-K, and 8-K filings for official figures and dates).
- Major market-data providers for micro-cap stock snapshots and historical price data (e.g., Yahoo Finance, MarketWatch, StockAnalysis).
- Clinical and rehabilitation journals for published case studies of myoelectric orthoses and outcome data.
As of June 30, 2024, per official company press releases and the company’s most recent SEC filings, the above descriptions reflect Myomo’s public disclosures and common market-data summaries. Always verify numeric values and the most recent developments directly via the cited sources.
External links
- Official corporate website and investor relations page (consult the company’s site for press releases and investor materials).
- SEC filings database for the company’s 10-Q, 10-K, and Form 8-K filings.
- Market quote pages on major data providers for live price, volume, 52-week range, and market-cap snapshots.
Further exploration: track myo stock in your watchlist on Bitget for real-time quotes and execute trades or set alerts using the platform’s order tools. For onboarding and custody across digital ecosystems, consider Bitget Wallet.
Disclosure: This article is informational and educational in nature. It is not investment advice, an offer to buy or sell securities, or a recommendation to trade myo stock. Readers should consult the company’s official filings and a licensed financial professional before making investment decisions.
